# Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination

> **NCT02342067** · PHASE1 · COMPLETED · sponsor: **Tobira Therapeutics, Inc.** · enrollment: 20 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Cenicriviroc
- **DRUG:** Pioglitazone

## Key facts

- **NCT ID:** NCT02342067
- **Lead sponsor:** Tobira Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12
- **Primary completion:** 2015-03
- **Final completion:** 2015-04
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2015-05-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02342067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02342067, "Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02342067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*